title: Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study.
abstract: BACKGROUND
  To evaluate the efficacy of BCNU, cisplatin, and vincristine (BCV regimen) in a prospective nonrandomized study among newly diagnosed children with high-grade glioma.
  
  
  METHODS
  Following surgery, patients received a combination of BCNU + cisplatin + VP16 (BCV), over 3 consecutive days. Patients with residual tumor continued this regimen unless no further improvement was observed on MRI, for a maximum of six courses. Patients who underwent complete surgical resection received six courses of adjuvant BCV.
  
  
  RESULTS
  Seventy-three patients were enrolled. Out of 66 eligible patients with central pathology review, the diagnosis of high-grade glioma was confirmed in 53 cases. The response rate was 20%. With a median follow-up of 128 months, 5- and 10-year event free survival rates are 16 +/- 9 and 13.3 +/- 9.4%. In univariate analysis, two prognostic factors were statistically significant: extent of resection and tumor location, while macroscopic total resection was the only significant prognostic factor in the multivariate analysis. The response to BCV did not translate into improved event free survival. Interstitial pneumonitis occurred in seven patients, leading to six deaths.
  
  
  CONCLUSIONS
  This BCV regimen could not be recommended in the treatment of high-grade gliomas in children, according to its lack of efficacy and its unacceptable pulmonary toxicity.
authors.affiliation: Department of Pediatric Oncology, CHU Nancy, Hôpital d'Enfants, Vandoeuvre Lès Nancy, France. p.chastagner@chu-nancy.fr
authors.forename: P
authors.initials: P
authors.lastname: Chastagner
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: F
authors.initials: F
authors.lastname: Doz
authors.forename: E
authors.initials: E
authors.lastname: Bouffet
authors.forename: J C
authors.initials: JC
authors.lastname: Gentet
authors.forename: M M
authors.initials: MM
authors.lastname: Ruchoux
authors.forename: S
authors.initials: S
authors.lastname: Bracard
authors.forename: E
authors.initials: E
authors.lastname: Desandes
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D005602:France; D005910:Glioma / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000401:mortality; D008297:Male; D008495:Medical Oncology; D010372:Pediatrics; D010865:Pilot Projects; D011446:Prospective Studies; D012955:Societies, Medical; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D002945:Cisplatin; D002330:Carmustine